Saltar al contenido
Merck
Todas las fotos(1)

Documentos clave

T2005000

Triflusal

European Pharmacopoeia (EP) Reference Standard

Sinónimos:

α,α,α-trifluoro-2,4-cresotic acid acetate, 2-(Acetyloxy)-4-(trifluoromethyl)benzoic acid, Drisgen, acetyl-4-trifluoromethylsalicylic acid

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización

Seleccione un Tamaño

50 MG
MXP 2,560.00

MXP 2,560.00

Check Cart for Availability
Solicitar un pedido a granel
Todas las fotos(1)

Seleccione un Tamaño

Cambiar Vistas
50 MG
MXP 2,560.00

About This Item

Fórmula empírica (notación de Hill):
C10H7F3O4
Número de CAS:
322-79-2
Peso molecular:
248.16
Código UNSPSC:
41116107
NACRES:
NA.24

MXP 2,560.00

Check Cart for Availability
Solicitar un pedido a granel

grado

pharmaceutical primary standard

familia API

triflusal

fabricante / nombre comercial

EDQM

aplicaciones

pharmaceutical (small molecule)

Formato

neat

temp. de almacenamiento

2-8°C

cadena SMILES

FC(F)(F)c1cc(c(cc1)C(=O)O)OC(=O)C

InChI

1S/C10H7F3O4/c1-5(14)17-8-4-6(10(11,12)13)2-3-7(8)9(15)16/h2-4H,1H3,(H,15,16)

Clave InChI

RMWVZGDJPAKBDE-UHFFFAOYSA-N

¿Está buscando productos similares? Visita Guía de comparación de productos

Categorías relacionadas

Descripción general

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Aplicación

Triflusal EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Acciones bioquímicas o fisiológicas

Triflusal is an anti-inflammatory antithrombotic platelet aggregation inhibitor with a 3-fold mechanism of action.
Triflusal is an anti-inflammatory antithrombotic platelet aggregation inhibitor with a 3-fold mechanism of action. It is an irreversible inhibitor of COX-1 inhibiting thromboxane A2, preventing aggregation; it preserves vascular prostacyclin, thus promoting anti-aggregant effect. Triflusal blocks phosphodiesterase leading to an increase in cAMP levels promoting anti-aggregant effect due to inhibition of calcium mobilization.

Envase

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Otras notas

Sales restrictions may apply.

Pictogramas

Exclamation mark
GHS07

Palabra de señalización

Warning

Frases de peligro

H302,H315,H317,H319,H335

Clasificaciones de peligro

Acute Tox. 4 Oral - Eye Irrit. 2 - Skin Irrit. 2 - Skin Sens. 1 - STOT SE 3

Órganos de actuación

Respiratory system

Código de clase de almacenamiento

11 - Combustible Solids

Clase de riesgo para el agua (WGK)

WGK 3

Punto de inflamabilidad (°F)

Not applicable

Punto de inflamabilidad (°C)

Not applicable

Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documentos section.

Si necesita más asistencia, póngase en contacto con Atención al cliente

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

David Murdoch et al.
Drugs, 66(5), 671-692 (2006-04-20)
Triflusal (Aflen, Disgren, Tecnosal, Triflux) is a novel platelet antiaggregant with structural similarities to salicylates, but which is not derived from aspirin. It has similar efficacy to aspirin in patients with cerebral or myocardial infarction, but has a reduced risk
José Antonio González-Correa et al.
Cardiovascular drug reviews, 24(1), 11-24 (2006-08-31)
Triflusal is a derivative of salicylic acid with a well-established platelet aggregation inhibitory profile. Its pharmacokinetic and pharmacodynamic properties differ, however, somewhat from those of acetylsalicylic acid. A number of recent experimental and clinical studies have shown that triflusal is
Triflusal: an old drug in modern antiplatelet therapy. Review of its action, use, safety and effectiveness.
Hector Anninos et al.
Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese, 50(3), 199-207 (2009-05-26)
J Alvarez Sabín et al.
Revista de neurologia, 27(160), 951-955 (1999-02-10)
Different studies have shown that aspirin (AAS), in low doses, may lead to a considerable frequency of hemorrhagic complications when used in the long term. We compare the long-term occurrence of hemorrhagic complications with low doses of AAS and high
J Costa et al.
The Cochrane database of systematic reviews, (3)(3), CD004296-CD004296 (2005-07-22)
Aspirin is the standard treatment for secondary prevention of stroke and other vascular events. Several studies suggest that triflusal may have a better safety profile. To determine in people at high risk of vascular events whether triflusal is an effective
Ver todos los artículos relacionados

Questions

Reviews

No rating value

Active Filters

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico